Biosynth Carbosynth and Shengquan Acquire New Plant to Increase Production Capacities in China

Leading life sciences reagents and custom synthesis and manufacturing services company, Biosynth Carbosynth, and Jinan Shengquan Group Share-Holding Co, Ltd have announced their acquisition of Kexing Biopharmaceutical Co, Ltd’s raw material factory in Jinan, China. With this acquisition, Biosynth Carbosynth’s and Shengquan’s joint venture Carbotang expands the production capacities significantly. The more than 30,000 m² property contains a comprehensive factory building on 5 floors, a demo workshop and a large warehouse including a state-of-the-art dangerous material storage. The expansion through a further production site now allows the group more flexibility and larger production volumes together with an increased production reliability. This is an essential prerequisite in the production of Biosynth Carbosynth’s products.

Dr Urs Spitz, CEO of Biosynth Carbosynth said: “We are delighted to be further expanding our manufacturing operations and hugely successful joint venture. With this strategic acquisition we can continue to deliver our enormous range of products at increasing scales, with unrivalled expertise in complex organic chemistries.”